Cellectis S.A. (CLLS) vs Inovio Pharmaceuticals (INO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Inovio Pharmaceuticals (INO) has outperformed Cellectis S.A. (CLLS) over the past year, losing 56.6% versus a loss of 69.8%. Over five years, CLLS leads with a -88.4% price change compared with -98.6% for INO. Cellectis S.A. is the larger company by market cap ($126.9 million vs $118.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | INO |
|---|---|---|
| Share price | $1.26 | $1.15 |
| Market cap | $126.92M | $118.91M |
| 1-day change | +0.80% | +5.50% |
| YTD return | -73.97% | -33.91% |
| 1-year return | -69.78% | -56.60% |
| 5-year return | -88.37% | -98.63% |
| EPS (TTM) | $-0.64 | $-0.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.48 | $2.72 |
| 52-week low | $1.22 | $0.56 |
| Distance from 52-week high | -77.01% | -57.72% |
| Analyst consensus | none | none |
| Avg. price target upside | +323.02% | +175.65% |
| Average volume | 80.14K | 3.90M |
| Shares outstanding | 72.73M | 103.40M |
| Employees | 224 | 112 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INO has outperformed CLLS by 13.2 percentage points over the past year.
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About Inovio Pharmaceuticals
INO stock →Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
CLLS vs INO FAQ
Which is bigger, Cellectis S.A. or Inovio Pharmaceuticals?
Cellectis S.A. (CLLS) is larger, with a market capitalization of $126.92M compared with $118.91M for Inovio Pharmaceuticals (INO).
Which stock has performed better over the past year, CLLS or INO?
INO returned -56.60% over the past 12 months, compared with -69.78% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and Inovio Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.